Hofseth Biocare ASA ((HOFBF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth Biocare ASA recently updated its clinical study titled ‘A Randomized Controlled Trial Investigating the Efficacy and Safety of Cardio® in Patient With Chronic Obstructive Pulmonary Disease.’ The study aims to explore the anti-inflammatory effects and potential reduction in cardiovascular disease risk using unrefined salmon oil as a dietary supplement in COPD patients. This research is significant as it builds on existing evidence suggesting marine foods’ health benefits.
The intervention under investigation is CARDIO®, a dietary supplement containing unrefined salmon oil, rich in omega fatty acids. It is intended to provide anti-inflammatory benefits and reduce cardiovascular risks in COPD patients. The study also includes a placebo group receiving medium-chain triglyceride oil.
The study design is a randomized, parallel, double-blinded, placebo-controlled trial aimed at prevention. Participants, care providers, and investigators are masked to ensure unbiased results.
Key dates include the initial submission on October 29, 2021, and the latest update on September 23, 2025. The study was withdrawn, indicating a halt in progress, which is crucial for stakeholders to note.
The withdrawal of this study could impact Hofseth Biocare ASA’s stock performance and investor sentiment, as it may delay potential market entry of CARDIO®. Investors should watch for industry developments and competitor actions in the dietary supplement market.
The study has been withdrawn, and further details can be accessed on the ClinicalTrials portal.